Pharsight

Posluma patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11413360 BLUE EARTH Dual mode radiotracer and—therapeutics
Nov, 2038

(14 years from now)

Posluma is owned by Blue Earth.

Posluma contains Flotufolastat F-18 Gallium.

Posluma has a total of 1 drug patent out of which 0 drug patents have expired.

Posluma was authorised for market use on 25 May, 2023.

Posluma is available in solution;intravenous dosage forms.

Posluma can be used as positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen (psa) level.

Drug patent challenges can be filed against Posluma from 26 May, 2027.

The generics of Posluma are possible to be released after 22 November, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 25, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient

NCE-1 date: 26 May, 2027

Market Authorisation Date: 25 May, 2023

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

POSLUMA family patents

Family Patents